Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020 Jun 18;382(25):2419-2430. [2]Lin Shen,1 Ping Chen, Jin Lu, et al.Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive locally advanced/metastatic gastric or ...
2024 ESMO Asia. 129MO. [2] D. Oh, W. Yeo, J. Chen, et al. Real-world treatment (Tx) patterns in patients (pts) with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (HER2+ aGC/GEJC) in East Asia (HER2+ GASTA). 2024 ESMO Asia. 182P....
研究题目 Updated Efficacy and Safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer SOX方案联合伊尼妥单抗作为HER2阳性晚期胃癌一线治疗的有效性和安全性数据更新 研究背景 HER2阳性晚期胃癌患者的预后较差。目前，曲妥珠单抗联合化疗是该类患者的一线标准...
[5] Kong Y, Dong Q, Jin P, et al.Updated Efficacy and Safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer. ESMO ASIA.2024.158P. [6] Janjigian, Y.Y., ...
2023年8月16日，浙江大学医学院附属第一医院肿瘤外科滕理送教授和浙江大学基础医学院免疫研究所周全研究员团队在Advanced Science上在线发表了题为Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis的研究论文。该...
1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, ran...
2023年8月，浙江大学医学院附属第一医院滕理送、周全研究团队在期刊Advanced Science（IF14.3）发表了一篇题为“Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis”的文章。#1 摘要 Abstract 大多数人类表皮...
今天给大家分享一篇类器官模型在新药研发中的应用,2023年8月16日由浙江大学滕理送教授团队发表在Advanced Science上的题为“Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis”的文章,利用细胞系、PDX、PDXO模...
[2].Janjigian Y Y,Kawazoe A,Yañez P,et al.The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J].Nature,2021,600(7890):727-730. [3].Collins D M,Madden S F,Gaynor N,et al.Effects of HER family–targeting tyrosine kinase inhibitors on antibody-...
[8] NCCN Gastric Cancer. 2023 V1. [9] Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal juncti...